Welcome to our dedicated page for Maravai Lifesciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai Lifesciences Holdings stock.
Maravai LifeSciences Holdings, Inc. reports recurring developments as a life sciences supplier of reagents and services for drug therapy, diagnostics, vaccine and human disease research. Company updates center on its TriLink nucleic acid synthesis business, including mRNA, oligonucleotides and CleanCap-related technologies, and its Cygnus biologics safety testing business, including host cell protein ELISA kits, impurity detection assays, reagents and services.
News about MRVI commonly covers quarterly financial results, segment revenue trends, guidance, restructuring and operating cost initiatives, investor conference participation, executive and board changes, and product or commercial updates tied to researchers, biotech innovators, vaccine developers, diagnostics companies and cell and gene therapy customers.
Maravai LifeSciences Holdings, Inc. (MRVI) announced an upsized public offering of 18,000,000 shares of Class A common stock at a price of $31.25 per share. This offering, increased by 3,000,000 shares from previous announcements, includes a 30-day option for underwriters to purchase an additional 2,700,000 shares. The offering is set to close on April 12, 2021. Notably, Maravai will not receive proceeds from this sale, which is managed by firms including Morgan Stanley, Jefferies, and Goldman Sachs.
Maravai LifeSciences Holdings (NASDAQ: MRVI) announced a public offering of 15,000,000 shares of its Class A common stock by selling stockholders, with an option for underwriters to purchase an additional 2,250,000 shares. The company will not receive any proceeds from this offering. Morgan Stanley, Jefferies, and Goldman Sachs are the joint managers for the offering. The registration statement is pending effectiveness, and the shares can't be sold until it becomes effective. Maravai provides essential life science products for drug therapies, diagnostics, and vaccine development.
Maravai LifeSciences Holdings, Inc. (MRVI) announced preliminary revenue estimates for Q1 2021, expecting approximately $148 million, which represents a 190% increase compared to Q1 2020 and a sequential rise of 50% from Q4 2020. The estimates exceed previous guidance of 30% to 35% growth. Income from Operations is projected to be between $80 million and $100 million. Revenues are primarily driven by strong performance in the Nucleic Acid Production segment, which accounts for $123.6 million, marking a 305% increase year-over-year.
Maravai LifeSciences (NASDAQ: MRVI) has enhanced its contract development and manufacturing capabilities with the launch of new plasmid DNA (pDNA) manufacturing services at TriLink BioTechnologies. This integrated offering aims to streamline the production of GMP-grade mRNA products, addressing the expected rise in global demand. CEO Carl Hull emphasized the importance of this development in reducing production timelines and alleviating sourcing delays. The state-of-the-art facility is equipped for GMP-grade plasmid production, supporting various therapeutic applications, including mRNA vaccines.
Maravai LifeSciences reported robust financial results for Q4 and the full year 2020, with revenue of $98.4 million for Q4 and $284.1 million for the year, reflecting increases of 173.5% and 98.5% year-over-year, respectively. Key drivers included a 338.4% surge in nucleic acid production revenue to $77.8 million, largely due to demand for mRNA technologies. The company projects 2021 revenue guidance between $580 million and $630 million, indicating growth of 104.2% to 121.8%. Net income for Q4 was $14.5 million, a significant turnaround from a loss of $5.5 million in Q4 2019.
Maravai LifeSciences, Inc. (NASDAQ: MRVI) announced its participation in two virtual investor conferences. CEO Carl Hull will present at the Cowen Health Care Conference on March 3, 2021, at 10:20 a.m. PT. He will also engage in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 23, 2021, at 8:30 a.m. PT. Webcasts of these events will be accessible via Maravai's investor relations website, with archived versions available shortly after the events.
Maravai LifeSciences (NASDAQ: MRVI) announced a new patent (No. 10,913,768) issued for its CleanCap technology, enhancing mRNA vaccine and therapeutic development. This patent represents the third for CleanCap, which improves the co-transcriptional capping process in synthetic mRNA production. The technology streamlines manufacturing, decreases costs, and accelerates the production of mRNA, critical for personalized cancer therapies and rapid vaccine responses. Maravai continues to lead in providing essential products for drug therapies, diagnostics, and vaccine research.
Maravai LifeSciences (NASDAQ: MRVI) is set to release its fourth quarter and full year 2020 financial results on March 2, 2021, after market close. A conference call will follow the announcement at 2:00 PM PT/5:00 PM ET, allowing analysts and investors to discuss the outcomes. Interested participants can join by dialing the provided numbers and using the conference ID 4090862. Maravai specializes in life science reagents and services, supporting drug therapies, diagnostics, and vaccine development for major biotech and biopharmaceutical companies.
Maravai LifeSciences (MRVI) successfully closed its initial public offering, selling 69 million shares of Class A common stock at $27 per share. This offering, which included 9 million additional shares due to underwriters' exercise, raised gross proceeds of approximately $1.86 billion before expenses. The stock began trading on the Nasdaq Global Select Market on November 20, 2020. Major investment banks involved in the offer included Morgan Stanley, Jefferies, and Goldman Sachs & Co. LLC. The funds raised will likely support Maravai's operations in life sciences, aiding drug therapies and research.
Maravai LifeSciences Holdings (MRVI) has priced its upsized initial public offering at $27.00 per share, offering 60,000,000 shares of Class A common stock, resulting in gross proceeds of $1.62 billion. The shares will commence trading on the Nasdaq under the ticker MRVI on November 20, 2020, with the offering closing expected by November 24, 2020. The underwriters have a 30-day option to buy an additional 9,000,000 shares. Maravai specializes in life science reagents and services crucial for drug development and diagnostics.